RxDoctor Payments DataLook up a doctor →

Thomas Giudice, MD

Urogynecology and Reconstructive Pelvic Surgery · West Columbia, SCNPI 1497735757

Payments from drug & device makers

$418,124in general payments, 2019–2025

Across 550 payments — averaging $760.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$342K
  • Valencia Technologies Corporation$39K
  • Coloplast$29K
  • Medtronic$2K
  • Axonics, Inc.$2K
  • Applied Medical Resources Corporation$849
  • plus $4K from 37 others

What the payments were for

  • Consulting fees$59,26614%
  • Speaking & faculty fees$289,82569%
  • Travel & lodging$30,9907%
  • Food & beverage$11,9793%
  • Education$26,0646%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urogynecology and reconstructive pelvic surgery providers in South Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$330,871
Medicare patients
594
Services billed
11,446

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron302$168,932
GemtesaVibegron188$117,643
PremarinEstrogens, Conjugated45$18,776
Tolterodine Tartrate ErTolterodine Tartrate240$14,729
Mirabegron ErMirabegron30$11,138
Estradiol192$9,734
LinzessLinaclotide16$8,205
Solifenacin Succinate131$5,736
Methenamine Hippurate109$5,641
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst233$2,396
Trospium Chloride65$2,234
Oxybutynin Chloride ErOxybutynin Chloride147$1,929
NitrofurantoinNitrofurantoin Macrocrystal62$1,346
Clobetasol Propionate24$1,239
Estradiol (Twice Weekly)Estradiol27$1,209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$736$168,932302 claims
Sumitomo Pharma America, Inc.Gemtesa$178$117,643188 claims
PfizerPremarin$184$18,77645 claims
AbbVieLinzess$627$8,20516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in South Carolinaon file to place this against a meaningful peer group, so we don't.

Other urogynecology and reconstructive pelvic surgery in West Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →